Mesenchymal stromal cells (MSCs) are rare progenitor cells that can be isolated from various tissues. They exhibit multilineage differentiation potential, support regenerative processes, and interact with various immune cells. Therefore, MSCs represent a promising tool for regenerative medicine. However, source-dependent and donor-dependent differences of MSC properties, including implications on their clinical application are still largely unknown. We evaluated MSCs derived from perinatal tissues umbilical cord (UC) and amniotic membrane (AM) in comparison to adult MSCs from bone marrow (BM), which were used as gold standard. We found genetic background-independent differences between MSCs from UC and AM. While AM- and UC-MSCs were closer to each other than to BM-MSCs, they also exhibited differences between each other. AM-MSCs from different donors but not UC-MSCs displayed high interdonor variability. In addition, we show that although all MSCs expressed similar surface markers, MSC populations from UC and AM showed differential profiles of gene expression and paracrine factor secretion to BM-derived MSCs. Notably, pathway analysis of gene expression data revealed intriguing differences between MSCs suggesting that MSCs from UC and AM possess in general a higher potential of immunomodulatory capacity, whereas BM-MSCs showed a higher potential of supporting regenerative processes as exemplified by neuronal differentiation and development. These differences between perinatal and BM-derived MSCs may be relevant for clinical applications.
Get full access to this article
View all access options for this article.
References
1.
ParekkadanB, MilwidJM. 2010. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng, 12:87–117.
2.
HussR. 2010. Stem cell therapeutics: hope for patients and biopharma!Stem Cells Dev, 19:593–594.
SingerNG, CaplanAI. 2011. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech Dis, 6:457–478.
5.
BiancoP, CaoX, FrenettePS, MaoJJ, RobeyPG, SimmonsPJ, WangCY. 2013. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med, 19:35–42.
6.
Le BlancK, MougiakakosD. 2012. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol, 12:383–396.
7.
CrisanM, YapS, CasteillaL, ChenCW, CorselliM, ParkTS, AndrioloG, SunB, ZhengBet al.2008. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell, 3:301–313.
8.
da SilvaML, ChagastellesPC, NardiNB. 2006. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci, 119:2204–2213.
ZukPA, ZhuM, MizunoH, HuangJ, FutrellJW, KatzAJ, BenhaimP, LorenzHP, HedrickMH. 2001. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng, 7:211–228.
11.
KuciaM, HalasaM, WysoczynskiM, Baskiewicz-MasiukM, MoldenhawerS, Zuba-SurmaE, CzajkaR, WojakowskiW, MachalinskiB, RatajczakMZ. 2007. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia, 21:297–303.
12.
SeshareddyK, TroyerD, WeissML. 2008. Method to isolate mesenchymal-like cells from Wharton's jelly of umbilical cord. Methods Cell Biol, 86:101–119.
13.
In't AnkerPS, ScherjonSA, Kleijburg-van derKC, NoortWA, ClaasFH, WillemzeR, FibbeWE, KanhaiHH. 2003. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood, 102:1548–1549.
IlancheranS, MoodleyY, ManuelpillaiU. 2009. Human fetal membranes: a source of stem cells for tissue regeneration and repair?Placenta, 30:2–10.
16.
ProckopDJ, OhJY. 2012. Medical therapies with adult stem/progenitor cells (MSCs): a backward journey from dramatic results in vivo to the cellular and molecular explanations. J Cell Biochem, 113:1460–1469.
17.
ProckopDJ. 2009. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther, 17:939–946.
18.
DominiciM, LeBK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD, HorwitzE. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
19.
BakshD, YaoR, TuanRS. 2007. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells, 25:1384–1392.
20.
KernS, EichlerH, StoeveJ, KlueterH, BiebackK. 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294–1301.
21.
BarlowS, BrookeG, ChatterjeeK, PriceG, PelekanosR, RossettiT, DoodyM, VenterD, PainS, GilshenanK, AtkinsonK. 2008. Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev, 17:1095–1107.
22.
BiebackK, KernS, KocaomerA, FerlikK, BugertP. 2008. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Biomed Mater Eng, 18:S71–S76.
KitaK, GauglitzGG, PhanTT, HerndonDN, JeschkeMG. 2010. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev, 19:491–501.
SarugaserR, LickorishD, BakshD, HosseiniMM, DaviesJE. 2005. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells, 23:220–229.
27.
ParoliniO, AlvianoF, BagnaraGP, BilicG, BuhringHJ, EvangelistaM, HennerbichlerS, LiuB, MagattiMet al.2008. Concise review: isolation and characterization of cells from human term placenta: outcome of the First International Workshop on Placenta Derived Stem Cells. Stem Cells, 26:300–311.
28.
BourinP, GadelorgeM, PeyrafitteJA, Fleury-CappellessoS, GomezM, RageC, SensebeL. 2008. Mesenchymal progenitor cells: tissue origin, isolation and culture. Transfus Med Hemotherapy, 35:160–167.
29.
KuznetsovSA, MankaniMH, BiancoP, RobeyPG. 2009. Enumeration of the colony-forming units-fibroblast from mouse and human bone marrow in normal and pathological conditions. Stem Cell Res, 2:83–94.
30.
MeisnerLF, JohnsonJA. 2008. Protocols for cytogenetic studies of human embryonic stem cells. Methods, 45:133–141.
31.
LeeRH, SeoMJ, PulinAA, GregoryCA, YlostaloJ, ProckopDJ. 2009. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood, 113:816–826.
32.
MollG, Rasmusson-DuprezI, von BahrL, Connolly-AndersenAM, ElgueG, FunkeL, HamadOA, LonniesH, MagnussonPUet al.2012. Are therapeutic human mesenchymal stromal cells compatible with human blood?Stem Cells, 30:1565–1574.
33.
CrisanM, ChenCW, CorselliM, AndrioloG, LazzariL, PeaultB. 2009. Perivascular multipotent progenitor cells in human organs. Ann N Y Acad Sci, 1176:118–123.
34.
DeasyBM, SchugarRC, ChirieleisonSM, WescoeKE, SchmidtBT, AskewY, NanceJJ, EvronJM, PeaultB. 2009. High harvest yield, high expansion, and phenotype stability of CD146 mesenchymal stromal cells from whole primitive human umbilical cord tissue. J Biomed Biotechnol, 2009:789526.
35.
DelormeB, RingeJ, GallayN, VernYL, KerboeufD, JorgensenC, RossetP, SensebeL, LayrolleP, HapuplT, CharbordP. 2008. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood, 111:2631–2635.
36.
BuhringHJ, BattulaVL, TremlS, ScheweB, KanzL, VogelW. 2007. Novel markers for the prospective isolation of human MSC. Ann N Y Acad Sci, 1106:262–271.
37.
KozanogluI, BogaC, OzdoguH, SozerO, MaytalmanE, YaziciAC, SahinFI. 2009. Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification. Cytotherapy, 11:527–533.
38.
ChackoSM, AhmedS, SelvendiranK, KuppusamyML, KhanM, KuppusamyP. 2010. Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol, 299:C1562–C1570.
39.
SonBR, Marquez-CurtisLA, KuciaM, WysoczynskiM, TurnerAR, RatajczakJ, RatajczakMZ, Janowska-WieczorekA. 2006. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells, 24:1254–1264.
40.
IshigeI, Nagamura-InoueT, HondaMJ, HarnprasopwatR, KidoM, SugimotoM, NakauchiH, TojoA. 2009. Comparison of mesenchymal stem cells derived from arterial, venous, and Wharton's jelly explants of human umbilical cord. Int J Hematol, 90:261–269.
41.
GaudinoG, FollenziA, NaldiniL, CollesiC, SantoroM, GalloKA, GodowskiPJ, ComoglioPM. 1994. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J, 13:3524–3532.
42.
ZambidisET, ParkTS, YuW, TamA, LevineM, YuanX, PryzhkovaM, PeaultB. 2008. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood, 112:3601–3614.
43.
KuciS, KuciZ, KreyenbergH, DeakE, PutschK, HueneckeS, AmaraC, KollerS, RettingerEet al.2010. CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica, 95:651–659.
44.
MariottiE, MirabelliP, AbateG, SchiattarellaM, MartinelliP, FortunatoG, DiNR, DelVL. 2008. Comparative characteristics of mesenchymal stem cells from human bone marrow and placenta: CD10, CD49d, and CD56 make a difference. Stem Cells Dev, 17:1039–1041.
45.
ChangCJ, YenML, ChenYC, ChienCC, HuangHI, BaiCH, YenBL. 2006. Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells, 24:2466–2477.
OrtizLA, DuTreilM, FattmanC, PandeyAC, TorresG, GoK, PhinneyDG. 2007. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A, 104:11002–11007.
48.
da Silva MeirellesL, FontesAM, CovasDT, CaplanAI. 2009. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev, 20:419–427.
49.
NewmanRE, YooD, LeRouxMA, nilkovitch-MiagkovaA. 2009. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets, 8:110–123.
50.
SonciniM, VertuaE, GibelliL, ZorziF, DenegriM, AlbertiniA, WenglerGS, ParoliniO. 2007. Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med, 1:296–305.
51.
JunkerJP, SommarP, SkogM, JohnsonH, KratzG. 2010. Adipogenic, chondrogenic and osteogenic differentiation of clonally derived human dermal fibroblasts. Cells Tissues Organs, 191:105–118.
52.
JonesS, HorwoodN, CopeA, DazziF. 2007. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol, 179:2824–2831.
53.
PratamaG, VaghjianiV, TeeJY, LiuYH, ChanJ, TanC, MurthiP, GargettC, ManuelpillaiU. 2011. Changes in culture expanded human amniotic epithelial cells: implications for potential therapeutic applications. PLoS One, 6:e26136.
54.
MagattiM, DeMS, VertuaE, GibelliL, WenglerGS, ParoliniO. 2008. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells, 26:182–192.
55.
BartholomewA, SturgeonC, SiatskasM, FerrerK, McIntoshK, PatilS, HardyW, DevineS, UckerDet al.2002. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol, 30:42–48.
56.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS, GianniAM. 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
57.
UccelliA, MorettaL, PistoiaV. 2008. Mesenchymal stem cells in health and disease. Nat Rev Immunol, 8:726–736.
JiYR, YangZX, HanZB, MengL, LiangL, FengXM, YangSG, ChiY, ChenDD, WangYW, HanZC. 2012. Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem, 30:1526–1537.
60.
MagattiM, De MunariS, VertuaE, NassautoC, AlbertiniA, WenglerGS, ParoliniO. 2009. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant, 18:899–914.
61.
LiuKJ, WangCJ, ChangCJ, HuHI, HsuPJ, WuYC, BaiCH, SytwuHK, YenBL. 2011. Surface expression of HLA-G is involved in mediating immunomodulatory effects of placenta-derived multipotent cells (PDMCs) towards natural killer lymphocytes. Cell Transplant, 20:1721–1730.
62.
WolbankS, PeterbauerA, FahrnerM, HennerbichlerS, van GriensvenM, StadlerG, RedlH, GabrielC. 2007. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng, 13:1173–1183.
63.
YooKH, JangIK, LeeMW, KimHE, YangMS, EomY, LeeJE, KimYJ, YangSKet al.2009. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell Immunol, 259:150–156.
64.
NautaAJ, KruisselbrinkAB, LurvinkE, WillemzeR, FibbeWE. 2006. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol, 177:2080–2087.
TondreauT, LagneauxL, DejeneffeM, MassyM, MortierC, DelforgeA, BronD. 2004. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation, 72:319–326.
67.
TakashimaY, EraT, NakaoK, KondoS, KasugaM, SmithAG, NishikawaS. 2007. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell, 129:1377–1388.
68.
MorikawaS, MabuchiY, NiibeK, SuzukiS, NagoshiN, SunaboriT, ShimmuraS, NagaiY, NakagawaT, OkanoH, MatsuzakiY. 2009. Development of mesenchymal stem cells partially originate from the neural crest. Biochem Biophys Res Commun, 379:1114–1119.
69.
GuleriaI, SayeghMH. 2007. Maternal acceptance of the fetus: true human tolerance. J Immunol, 178:3345–3351.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
